Their new findings, published Thursday by the U.S. Centers for Disease Control and Prevention, suggest that some vulnerable patients were not offered the prescription medicines at all, and that doctors need more education to make sure the drugs get to patients who could benefit.
Despite public alarm about Paxlovid rebound, in which symptoms recur after treatment, none of the medical records noted it as a reason not to offer the drug.
[
add
]
[
|
|
...
]